Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in I… Read more
Deciphera Pharmaceuticals Inc (D05) - Total Assets
Latest total assets as of March 2024: €420.93 Million EUR
Based on the latest financial reports, Deciphera Pharmaceuticals Inc (D05) holds total assets worth €420.93 Million EUR as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Deciphera Pharmaceuticals Inc - Total Assets Trend (2016–2023)
This chart illustrates how Deciphera Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Deciphera Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Deciphera Pharmaceuticals Inc's total assets of €420.93 Million consist of 80.5% current assets and 19.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.6% |
| Accounts Receivable | €31.95 Million | 6.8% |
| Inventory | €21.21 Million | 4.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how Deciphera Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Deciphera Pharmaceuticals Inc's current assets represent 80.5% of total assets in 2023, a decrease from 98.8% in 2016.
- Cash Position: Cash and equivalents constituted 17.6% of total assets in 2023, down from 97.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.8% of total assets.
Deciphera Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Deciphera Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Deciphera Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Deciphera Pharmaceuticals Inc generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Deciphera Pharmaceuticals Inc is currently not profitable relative to its asset base.
Deciphera Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.19 | 5.67 | 15.20 |
| Quick Ratio | 3.94 | 5.37 | 15.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €266.51 Million | € 392.25 Million | € 600.04 Million |
Deciphera Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Deciphera Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.95 |
| Latest Market Cap to Assets Ratio | 4.46 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | €473.57 Million |
| Market Capitalization | $2.11 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Deciphera Pharmaceuticals Inc's assets at a significant premium ( 4.46x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Deciphera Pharmaceuticals Inc's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Deciphera Pharmaceuticals Inc (2016–2023)
The table below shows the annual total assets of Deciphera Pharmaceuticals Inc from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €473.57 Million | +4.30% |
| 2022-12-31 | €454.04 Million | +5.72% |
| 2021-12-31 | €429.48 Million | -33.15% |
| 2020-12-31 | €642.43 Million | +3.22% |
| 2019-12-31 | €622.41 Million | +97.24% |
| 2018-12-31 | €315.56 Million | +58.50% |
| 2017-12-31 | €199.09 Million | +237.76% |
| 2016-12-31 | €58.95 Million | -- |